Drug intelligence / Profile preview

SFT-403

Development stage: Unknown
Lead developer: invoX Pharma
Modality: Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

SFT-403 is an inhaled therapeutic candidate being developed by Softhale (a subsidiary of invoX Pharma) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The drug is delivered via the proprietary Softhaler® inhalation platform, a propellant-free, multi-dose soft mist inhaler (SMI) designed to deliver medication deep into the lungs with high efficiency and minimal inspiratory effort. By utilizing this targeted delivery method, SFT-403 aims to concentrate the active therapeutic agent at the site of fibrotic disease in the lung tissue, potentially enhancing efficacy while reducing the systemic side effects often associated with oral antifibrotic treatments. As of early 2024, the program is in early-stage clinical development.

Beyond the preview

Go deeper on SFT-403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFT-403.

Explore the full profile